Skip to main content
SpringerLink
Log in

Therapie der Hepatitis C

Aktueller Stand und Perspektiven

Therapy for hepatitis C

State of the art and perspectives

  • Schwerpunkt: Virushepatitis
  • Published:
Der Gastroenterologe Aims and scope

Zusammenfassung

Die Standardtherapie der chronischer Hepatitis C (HCV) besteht aus einer Kombination eines pegylierten Interferons (PEG-IFN) und Ribavirin. Patienten mit HCV-Genotyp-1-Infektion werden für 48 Wochen therapiert und Patienten mit HCV-Genotyp-2- oder -3-Infektion für 24 Wochen. Unter Berücksichtigung von Genotyp, Ausgangsviruslast und initialem virologischen Ansprechen wird die Therapie in Zukunft stärker individualisiert werden. Möglicherweise wird mit Viramidine eine besser verträgliche Alternative zu Ribavirin zur Verfügung stehen, die seltener als Ribavirin eine Anämie induziert. Zahlreiche Substanzen befinden sich aktuell in präklinischer und klinischer Prüfung; erste Ergebnisse von Phase-I/II-Studien mit den spezifischen Inhibitoren der HCV-Protease und -Polymerase sind vielversprechend.

Abstract

The standard treatment for patients with chronic hepatitis C (HCV) is a combination therapy with pegylated interferon and ribavirin. Patients infected with HCV genotype 1 are treated for 48 weeks, and patients infected with HCV genotype 2 or 3 for 24 weeks. Using the HCV genotype together with a baseline viremia and the initial virologic response to therapy enables further individualization of treatment duration. Viramidine could become an alternative to ribavirin with a reduction of ribavirin induced anemia. Many new drugs are currently under investigation in preclinical and clinical studies. The first results of phase I/II studies with specific HCV protease and polymerase inhibitors are promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Afdhal N, Rodriguez-Torres M, Lawitz E et al. (2005) Enhanced antiviral efficacy for valopicitabine (NM283) plus PEG-interferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial. J Hepatol 42 (Suppl 2): 39A

    Google Scholar 

  2. Alberti A (2005) Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 42: 266–274

    Article  PubMed  Google Scholar 

  3. Bain V, Kaita K, Yoshida E et al. (2005) A phase 2 study to assess antiviral response safety, and pharmacokinetics of Albuferon in IFN-alfa naive subjects with genotype 1 chronic hepatitis C. J Hepatol 42 (Suppl 2): 9A

    Google Scholar 

  4. Berg T, Kronenberger B, Hinrichsen H et al. (2003) Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology 37: 1359–1367

    Article  PubMed  Google Scholar 

  5. Berg T, Sarrazin C, Herrmann E et al. (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37: 600–609

    Article  PubMed  Google Scholar 

  6. Berg T, von Wagner M, Hinrichsen H et al. (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology

    Google Scholar 

  7. Dalgard O, Bjoro K, Hellum KB et al. (2004) Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40: 1260–1265

    Article  PubMed  Google Scholar 

  8. Davis GL, Wong JB, McHutchison JG (2003) Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38: 645–652

    Article  PubMed  Google Scholar 

  9. Ferenci P, Bergholz U, Laferl H et al. (2005) Is shorter treatment with peginterferon alfa-2a (40KD) (PEGASYS(r)) plus ribavirin (COPEGUS(r)) possible in HCV genotype 1 ‚super-responders’? Preliminary results of a prospective randomized clinical trial. Hepatology 42 (Suppl1): 219A

    Google Scholar 

  10. Ferenci P, Brunner H, Laferl H et al. (2005) Interim analysis of a randomized, controlled study comparing the efficacy Of 40KD Peg-Interferon Alfa2a in combination with 800 mg or 400 mg Ribavirin pro Tagay in chronic hepatitis C, genotype 2/3. DDW abstract ID: 89

    Google Scholar 

  11. Ferenci P, Formann E, Laferl H et al. (2006) Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol 44: 275–282

    Article  PubMed  Google Scholar 

  12. Fried MW, Shiffman ML, Reddy KR et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982

    Article  PubMed  Google Scholar 

  13. Gerlach JT, Diepolder HM, Zachoval R et al. (2003) Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125: 80–88

    Article  PubMed  Google Scholar 

  14. Gish RG, Nelson D, Arora S et al. (2005) Virologic response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a. J Hepatol 42 (Suppl 2): 39A

    Google Scholar 

  15. Gordon SC, Bacon BR, Jacobson IM et al. (2003) Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks. Hepatology 38 (Suppl 1): 307A

    Google Scholar 

  16. Hadziyannis SJ, Sette HJr, Morgan TR et al. (2004) Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355

    PubMed  Google Scholar 

  17. Hinrichsen H, Benhamou Y, Wedemeyer H et al. (2004) Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology ; 127: 1347–1355

    Google Scholar 

  18. Horsmans Y, Berg T, Desager JP et al. (2005) Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology ; 42: 724–731

    Google Scholar 

  19. Jacobson IM, Brown RS, Freilich B et al. (2005) Weigt-based ribavirin dosing (WMD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, a US community based trial. Hepatology 42, Suppl.1: 749A

  20. Jaeckel E, Cornberg M, Wedemeyer H et al. (2001) Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 20: 1452–1457

    Article  Google Scholar 

  21. Jensen D, Morgan T, Marcellin P et al. (2005) Rapid virological response at week 4 (RVR) of peginterferon alfa-2a (40KD) (PEGASYS(r)) plus ribavirin (RBV, COPEGUS(r)) treatment predicts sustained virological response (SVR) after 24 weeks in genotye 1 patients. Hepatology ; 42 (Suppl 1): 650A

  22. Kamal SA, El Tawil AA, Nakano T et al. (2005) Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 54: 858–866

    Article  PubMed  Google Scholar 

  23. Kamal SM, Fouly AE, Kamel RR et al. (2006) Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130: 632–638

    Article  PubMed  Google Scholar 

  24. Mangia A, Ricci GL, Persico M et al. (2005) A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 12: 299

    Article  Google Scholar 

  25. Mangia A, Santoro R., Minerva N et al. (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609–2617

    Article  PubMed  Google Scholar 

  26. Manns MP, Berg T, Wedemeyer H et al. (2004) Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C non-responder patients. Hepatology 40(suppl 1): 251A

    Google Scholar 

  27. Manns MP, McHutchison JG, Gordon SC et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965

    Article  PubMed  Google Scholar 

  28. Mayer KE, Myers RP, Lee SS (2005) Silymarin treatment of viral hepatitis: a systemic review. J Viral Hepat 12: 559–567

    Article  PubMed  Google Scholar 

  29. McHutchison J, Bacon B, Gordon SC et al. (2005) Relationships of HCV RNA responses to CPG 10101, a TLR9 agonist: pharmacodynamics and patient characteristics. Hepatology 42 (Suppl 1): 249A

    Google Scholar 

  30. McHutchison JG, Gordon SC, Schiff ER et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485–1492

    Article  PubMed  Google Scholar 

  31. Nelson D, Rustgi V, Balan V et al. (2005)A phase 2 study of albuferon in combination with ribavirin in non-responders to prior interferon therapy for chronic hepatitis C. Hepatology ; 42 (Suppl 1): 278 A

  32. Nevens F, Roskams T, Van Vlierberghe H et al. (2003) A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38: 1092–1094

    Article  PubMed  Google Scholar 

  33. O’Brien C, Godofsky E, Rodriguez-Torres M et al. (2005) Randomized trial of valopicitabine (NM283), alone or with peg-interferon, vs. retreatment with PEG-interferon plus ribavirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to PEGIFN/RBV: first interim results. Hepatology 42 (Suppl 1): 234A

    Google Scholar 

  34. Poynard T, Marcellin P, Lee SS et al. (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352: 1426–1432

    Article  PubMed  Google Scholar 

  35. Reesink HW, Zeuzem S, van Vliet A et al. (2005) Final results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 42 (Suppl 1): 234A

    Google Scholar 

  36. Santantonio T, Fasano M, Sinisi E et al. (2005) Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. Hepatology 42: 329–333

    Article  Google Scholar 

  37. Shiffman ML, Price A, Hubbard S et al. (2005) Treatment of chronic hepatitis C virus (HCV) genotype 1 infection with peginterferon alfa-2b (PEGIFN), high weight based dose ribavirin (RVN) and epoetin alfa (EPO) enhances sustained virological response (SVR). Hepatology ; 42 (Suppl 1): 217A

  38. Wagner von M, Huber M, Berg T et al. (2005) Peginterferon alfa-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129: 522–527

    Article  PubMed  Google Scholar 

  39. Wiegand J, Buggisch P, Boecher W et al. (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET Acute-HCV-II Study. Hepatology 43: 250–256

    Article  PubMed  Google Scholar 

  40. Zeuzem S (2004) Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140: 370–381

    PubMed  Google Scholar 

  41. Zeuzem S, Diago M, Gane E et al. (2004) Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127: 1724–1732

    Article  PubMed  Google Scholar 

  42. Zeuzem S, Hultcrantz R, Bourliere M et al. (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J.Hepatol 40: 993–999

    Article  PubMed  Google Scholar 

  43. Zeuzem S, Pawlotsky JM, Lukasiewicz E et al. (2005) International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 250–257

  44. Zeuzem S, Sarrazin C, Rouzier R et al. (2005) Anti-viral activity of SCH503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) subjects refractory to pegylated interferon. Hepatology 42 (Suppl 1): 233A

    Google Scholar 

  45. Zeuzem S, Sarrazin C, Wagner F et al. (2005) Combination therapy with the HCV protease inhibitor SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron non-responders: phase IB results. Hepatology 42 (Suppl 1): 276A

    Article  Google Scholar 

  46. Zeuzem S, Buti M, Ferenci P et al. (2006) Efficacy of 24 weeks treatment with peginterferon alf-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44: 97–103

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Kirrberger Straße, 66421, Homburg/Saar

    M. Friedrich-Rust &  S. Zeuzem

Authors
  1. M. Friedrich-Rust
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Zeuzem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Zeuzem.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friedrich-Rust, M., Zeuzem, S. Therapie der Hepatitis C. Gastroenterologe 1, 126–132 (2006). https://doi.org/10.1007/s11377-006-0017-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11377-006-0017-x

Schlüsselwörter

Keywords

Search

Navigation